MORRISVILLE, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

MORRISVILLE, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the

MORRISVILLE, N.C. , June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar , M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical

MORRISVILLE, N.C. , June 09, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the Pulmonary

MORRISVILLE, N.C. , June 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company’s participation in the Jefferies Healthcare Conference . Mr. Michael Kaseta , Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022 ,

MORRISVILLE, N.C. , June 02, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 , at 11:00 am Eastern Time .

MORRISVILLE, N.C. , May 16, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the America Thoracic

-  Secured access to new capital through debt and equity transactions -  Increased utilization of Treprostinil Injection with increasing payer generic mandates -  Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder -  Company to

MORRISVILLE, N.C. , May 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 . The company will host a conference call and webcast at 8:30 a.m.

MORRISVILLE, N.C. , April 25, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 35,700 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022